The first 10 drugs selected for price negotiations under Medicare Part D program includes only one oncology drug: ibrutinib (Imbruvica), a tyrosine kinase inhibitor indicated for the treatment of blood cancers, including chronic lymphocytic leukemia and small lymphocytic lymphoma.
On April 15, President Trump signed a wide-ranging executive order that aims to lower drug prices, boost transparency into fees charged by middlemen, and limit Medicare payments for outpatient services provided by hospitals.
